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Abstract 
Transmucosal nasal delivery is a promising drug delivery 
option where common drug administrations (e.g., intravenous, 
intramuscular, or oral) are inapplicable. Recently, it has been 
shown that many drugs have better bioavailability by nasal 
route than by oral route. This has been attributed to rich 
vasculature and a highly permeable structure of the nasal 
mucosa coupled with avoidance of hepatic first-pass 
elimination, gut wall metabolism and/or destruction in the 
gastrointestinal tract. The physiology of the nose presents 
obstacles, but offers a promising route for non-invasive 
systemic delivery of numerous therapies and debatably drug 
delivery route to the brain.  To overcoming problems in nasal 
drug delivery requires deep understanding of the various 
factors affecting nasal delivery. Thus present review focuses on 
various aspects of nasal drug delivery with special emphasis to 
factors affecting nasal drug administration. 
Keywords: Transmucosal nasal delivery, hepatic first-pass 
metabolism, non-invasive, microemulsions, microspheres. 
 
Introduction 
Oral drug delivery is the most desirable route for 
drug administration whenever systemic effects 
are intended [1, 2]. But low oral bioavailability of 
some compounds has prompted the search of 
more effective routes for their systemic delivery 
[3]. Transmucosal routes of drug delivery (i.e., 
the mucosal linings of the nasal, rectal, vagina, 
ocular and oral cavity) offer distinct advantages 
over peroral administration for systemic drug 
delivery. These advantages includes possible 
bypass of the first pass effect, avoidance of pre-
systemic elimination of gastro intestinal tract and 
depending on the particular drug. The nasal 
cavity as a site for systemic drug delivery has 
been investigated by many research groups.  
However, the potential irritation and irreversible 
damage to the ciliary action application of nasal 
dosage forms, as well as the large intra and inter 
subject variability in mucus secretion in the nasal 
mucosa could significantly effect drug absorption 
from this site.  
 
Currently, many nasal drug products on the 
market are indicated for the treatment of local 
disease such as allergic rhinitis, pain and for 
centrally acting drugs where the direct pathway 
from the nose to brain might offer a quicker and 
further specific therapeutic effect. Many low-
molecular-weight, non-polar drugs (<300Da) in 
solution form are able to infiltrate the nasal 
epithelium with effortlessness. The effectiveness 
of a particular delivery system is also affected by 
its formulation as a liquid, powder [4], gel [5], 
microsphere [6], liposome [7] or nanoparticle [8]. 
Intranasal drug delivery is now recognized to be a 
useful and reliable alternative to oral and 
parenteral routes. In general, among the primary 
targets for intranasal administration are 
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pharmacologically active compounds with poor 
stability in gastrointestinal fluids, poor intestinal 
absorption and/or extensive hepatic first-pass 
elimination, such as peptides, proteins and polar 
drugs [9]. The nasal delivery seems to be a 
favorable way to circumvent the obstacles for 
blood-brain barrier (BBB) allowing the direct 
drug delivery in the biophase of central nervous 
system (CNS)-active compounds. It has also been 
considered to the administration of vaccines [10-
13].  
 
 
Fig : 1 
 
In addition, intranasal absorption avoids the 
gastrointestinal and hepatic pre-systemic 
metabolism, enhancing drug bioavailability in 
comparison with that obtained after 
gastrointestinal absorption [14,15]. Hence, it 
appears to be an appropriate route for the 
treatment of not only acute or chronic nasal 
diseases, but also for a range of acute or chronic 
conditions requiring considerable systemic drug 
exposure [9]. 
 
The present review outlines anatomical and 
physiological features of nasal cavity, the major 
factors affecting nasal drug delivery. 
Additionally, this review focuses on the strategies 
used to enhance the nasal drug absorption and 
research carried out on nasal drug delivery. 
 
Nasal anatomy and physiology of nose: 
The human nasal cavity has a total volume of 
about 16 to 19 ml, and a total surface area of 
about 180 cm2, and is divided into two nasal 
cavities via the septum. The volume of each 
cavity is approximately 7.5 ml, having a surface 
area around 75 cm2.  
 
The vestibular region: It is located at the 
opening of nasal passages and is responsible for 
filtering out the air borne particles. It is 
considered to be the least important of the three 
regions with regard to drug absorption. 
 
The respiratory region: The respiratory region 
is the largest having the highest degree of 
vascularity and is mainly responsible for systemic 
drug absorption. 
 
The olfactory region: It is of about 10 cm2 in 
surface area, and it plays a vital role in 
transportation of drugs to the brain and the CSF. 
Human olfactory region comprises of thick 
connective tissue lamina propria, upon which 
rests the olfactory epithelium. Lamina propria has 
axons, bowans bundle and blood vessels whereas 
epithelium consists of three different cells i.e. 
basal cells, supporting cells and olfactory 
receptor cells. Neurons are interspersed between 
supporting cells. The olfactory receptor cells are 
bipolar neurons with a single dendritic and 
extending from the cell body to the free apical 
surface where it ends in an olfactory knob 
carrying non-motile cilia, which extend above the 
epithelium. 
 
The epithelium of the nasal passage is covered by 
a mucus layer, which entraps particles. The 
mucus layer is cleared from the nasal cavity by 
cilia, and is renewed every 10 to 15 minutes [17]. 
The pH of the mucosal secretions ranges from 5.5 
to 6.5 in adults and 5.0 to 6.7 in children. The 
mucus moves through the nose at an approximate 
rate of 5 to 6 mm/min resulting in particle 
clearance within the nose every 15 to 20 minutes. 
Numerous enzymes for instance, cytochrome 
Dhakar et al. International Journal of Drug Delivery 3 (2011) 194-208 
 
P450 enzymes, carboxylesterases and glutathione 
S-transferases are found in nasal cavity[18-20]. 
 
Reason for Development of Nasal Delivery 
Nasal drug delivery is a useful delivery method 
for drugs that are active in low doses and show 
no or minimal oral bioavailability. The nasal 
route circumvents hepatic first pass elimination 
associated with the oral delivery: it is easily 
accessible and suitable for self-medication. 
Currently, tow classes of nasally delivered 
therapeutics are on the market. The first one 
comprises low molecular weight and hydrophobic 
drugs for the treatment of the nasal mucosa and 
sinus, including decongestants, topical steroids, 
antibiotics and other (OTC) products. The second 
class encompasses a few drugs, which have 
sufficient nasal absorption for displaying 
systemic effects. Important candidates are the 
compounds, generally administered by injection 
and hardly absorbed after oral administration, due 
to their instability in gastrointestinal tract, poor 
absorption properties, and their rapid and 
extensive biotransformation [21-23].  
 
Mechanism of drug absorption through nasal 
mucosa: 
The first step in the absorption of drug from the 
nasal cavity is passage through the mucus [22]. 
Small, unchanged particles easily pass through 
this layer. However, large or charged particles 
may find it more difficult to cross. Mucin, the 
principle protein in the mucus, has the potential 
to bind to solutes, hindering diffusion. 
Additionally, structural changes in the mucus 
layer are possible as a result of environmental 
changes (i.e. pH, temperature, etc.)[24]. 
Subsequent to a drug’s passage through the 
mucus, there are several mechanisms for 
absorption through the mucosa [25]. These 
include transcellular or simple diffusion across 
the membrane, paracellular transport via 
movement between cell and transcytosis by 
vesicle carriers [24]. Obstacles to drug absorption 
are potential metabolism before reaching the 
systemic circulation and limited residence time in 
the cavity. Several mechanisms have been 
proposed but the following two mechanisms have 
been considered predominantly.  
 
 
Figure 2: (1) Paracellular route (1a) Intercellular spaces, 
(1b) Tight junctions, (2) Transcellular route (2a) Passive 
diffusion, (2b) Active transport, (3) Transcytosis 
(modified)25 
 
The first mechanism involves an aqueous route of 
transport, which is also known as the paracellular 
route. This route is slow and passive. Insulin, 
mannitol and propranolol were absorbed through 
this mechanism. There is an inverse log-log 
correlation between intranasal absorption and the 
molecular weight of water-soluble compounds. 
Literature survey revealed that good 
bioavailability was observed for drugs with a 
molecular weight up to 1000 Daltons. But with 
the help of permeation enhancers good 
bioavailability can be enhanced to at least 6000 
Daltons26. The second mechanism involves 
transport through a lipoidal route that is also 
known as the transcellular process and is 
responsible for the transport of lipophilic drugs 
that show a rate dependency on their 
lipophilicity. Drugs also cross cell membranes by 
an active transport route via carrier-mediated 
means or transport through the opening of tight 
junctions [23]. For example, Chitosan, a natural 
biopolymer from shellfish, opens tight junctions 
between epithelial cells to facilitate drug 
transport [27]. 
 
Merits Of Intranasal Drug Delivery:[9, 14, 15, 
27, 28] 
9 Non – invasive, rapid, Self-administration 
thus improved convenience and 
compliance. 
9 Large nasal mucosal surface area for dose 
absorption  
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9 Bypasses the BBB and targets the CNS, 
reducing systemic exposure and thus 
systemic exposure and thus systemic side 
effects. 
9 Minimal aftertaste  
9 Does not require nay modification of the 
therapeutic agent being delivered 
neurological and psychiatric disorders. 
9 Rich vasculature and highly permeable 
structure of the nasal mucosa greatly 
enhance drug absorption. 
9 Problem of degradation of peptide drugs in 
minimized up to a certain extent. 
9 Easy accessibility to blood capillaries. 
 
Demerits of Intranasal Drug Delivery: [29, 30] 
9 Concentration achievable in different regions 
of the brain and spinal cord varies with each 
agent. 
9 Delivery is expected to decrease with 
increasing molecular weight of drug. 
9 Some therapeutic agents may be susceptible 
to partial degradation in the nasal mucosa or 
may cause irritation to the mucosa. 
9 Nasal congestion due to cold or allergies 
may interfere with this method of delivery. 
9 Frequent use of this route may result in 
mucosal damage. 
 
Factors affecting the characteristics of nasal 
drug delivery: 
Some of the physicochemical, formulation and 
physiological factors are imperative and must be 
considered prior to designing intranasal delivery.  
 
Physicochemical properties of drugs: 
Chemical form: The chemical form of a drug is 
important in determining absorption. 
 
For example, conversion of the drug into a salt or 
ester form can also alter its absorption. Huang et 
al 1985 studied the effect of structural 
modification of drug on absorption [31]. It was 
observed that in-situ nasal absorption of 
carboxylic acid esters of L-Tyrosine was 
significantly greater than that of L-Tyrosine. 
 
Polymorphism: Polymorphism is known to 
affect the dissolution rate and solubility of drugs 
and thus their absorption through biological 
membranes.  
 
Molecular Weight: A linear inverse correlation 
has been reported between the absorption of 
drugs and molecular weight up to 300 Da. 
Absorption decreases significantly if the 
molecular weight is greater than 1000 Da except 
with the use of absorption enhancers. Shape is 
also important. Linear molecules have lower 
absorption than cyclic – shaped molecules.  
 
Particle Size: It has been reported that particle 
sizes greater than 10μm are deposited in the nasal 
cavity.  
 
Solubility & dissolution Rate: Drug solubility 
and dissolution rates are important factors in 
determining nasal absorption from powders and 
suspensions. The particles deposited in the nasal 
cavity need to be dissolved prior to absorption. If 
a drug remains as particles or is cleared away, no 
absorption occurs. 
 
Formulation factors: 
pH of the formulation: Both the pH of the nasal 
cavity and pKa of a particular drug need to be 
considered to optimize systemic absorption. 
Nasal irritation is minimized when products are 
delivered with a pH range of 4.5 to 6.5. Also, 
volume and concentration are important to 
consider. The delivery volume is limited by the 
size of the nasal cavity. An upper limit of 25 
mg/dose and a volume of 25 to 200 μL/ nostril 
have been suggested. 
9 To avoid irritation of nasal mucosa; 
9 To allow the drug to be available in 
unionized form for absorption; 
9 To prevent growth of pathogenic bacteria in 
the nasal passage; 
9 To maintain functionality of excipients 
such as preservatives; and 
9 To sustain normal physiological ciliary 
movement. 
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Lysozyme is found in nasal secretions, which is 
responsible for destroying certain bacteria at 
acidic pH. Under alkaline conditions, lysozyme is 
inactivated and the nasal tissue is susceptible to 
microbial infection. It is therefore advisable to 
keep the formulation at a pH of 4.5 to 6.5 keeping 
in mind the physicochemical properties of the 
drug as drugs are absorbed in the unionized form.
  
 
 
Figure 3: Factors affecting nasal drug absorption and 
approaches to overcome them. 
 
Buffer Capacity: Nasal formulations are 
generally administered in small volumes ranging 
from 25 to 200μL. Hence, nasal secretions may 
alter the pH of the administrated dose. This can 
affects the concentration of unionized drug 
available for absorption. Therefore, an adequate 
formulation buffer capacity may be required to 
maintain the pH in-situ. 
 
Osmolarity: Drug absorption can be affected by 
tonicity of formulation. Shrinkage of epithelial 
cells has been observed in the presence of 
hypertonic solutions. Hypertonic saline solutions 
also inhibit or cease ciliary activity. Low pH has 
a similar effect as that of a hypertonic solution. 
 
Gelling / Viscosity building agents or gel-
forming carriers: Pennington et al 1988 studied 
that increase in solution viscosity may provide a 
means of prolonging the therapeutic effect of 
nasal preparations [32]. Suzuki et al 1999 showed 
that a drug carrier such as hydroxypropyl 
cellulose was effective for improving the 
absorption of low molecular weight drugs but did 
not produce the same effect for high molecular 
weight peptides  [33].  
 
Solubilizers: Aqueous solubility of drug is 
always a limitation for nasal drug delivery in 
solution. Conventional solvents or co-solvents 
such as glycols, small quantities of alcohol, 
Transcutol (diethylene glycol monoethyl ether), 
medium chain glycerides and Labrasol can be 
used to enhance the solubility of drugs [34]. 
Other options include the use of surfactants or 
cyclodextrins such as HP-β-cyclodextrin that 
serve as a biocompatible solubilizer and stabilizer 
in combination with lipophilic absorption 
enhancers.  
 
Preservatives: Most nasal formulations are 
aqueous based and need preservatives to prevent 
microbial growth. Parabens, benzalkonium 
chloride, phenyl ethyl alcohol, EDTA and 
benzoyl alcohol are some of the commonly used 
preservatives in nasal formulations. Van De Donk 
et al 1980 have shown that mercury containing 
preservatives have a fast and irreversible effect 
on ciliary movement and should not be used in 
the nasal systems [35]. 
 
Antioxidants: Usually, antioxidants do not affect 
drug absorption or cause nasal irritation. 
Commonly used antioxidants are sodium 
metabisulfite, sodium bisulfite, butylated 
hydroxyl toluene and tocopherol. 
 
Humectants: Many allergic and chronic diseases 
are often connected with crusts and drying of 
mucous membrane. Therefore humectants can be 
added especially in gel-based nasal products. 
Humectants avoid nasal irritation and are not 
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Nasal blood flow: Nasal mucosal membrane is 
very rich in vasculature and plays a vital role in 
the thermal regulation and humidification of the 
inhaled air. The blood flow and therefore the drug 
absorption will depend upon the vasoconstriction 
and vasodilatation of the blood vessels.  
likely to affect drug absorption. Common 
examples include glycerin, sorbitol and mannitol. 
 
Drug Concentration, Dose & Dose Volume: 
Drug concentration, dose and volume of 
administration are three interrelated parameters 
that impact the performance of the nasal delivery 
performance. Nasal absorption of L-Tyrosine was 
shown to increase with drug concentration in 
nasal perfusion experiments. 
 
Effect of Enzymatic Activity: Several enzymes 
that are present in the nasal mucosa might affect 
the stability of drugs. For example, proteins and 
peptides are subjected to degradation by 
proteases and amino-peptidase at the mucosal 
membrane. The level of amino-peptidase present 
is much lower than that in the gastrointestinal 
tract. Peptides may also form complexes with 
immunoglobulin (Igs) in the nasal cavity leading 
to an increase in the molecular weight and a 
reduction of permeability. 
 
Role of Absorption Enhancers: Absorption 
enhancers may be required when a drug exhibits 
poor membrane permeability, large molecular 
size, lack of lipophilicity and enzymatic 
degradation by amino peptidases. Osmolarity and 
pH may accelerate the enhancing effect. 
Absorption enhancers improve absorption 
through many different mechanisms, such as 
increasing membrane fluidity, increasing nasal 
blood flow, decreasing mucus viscosity, and 
enzyme inhibition.  
 
Effect of Mucociliary Clearance [36,37]: The 
absorption of drugs is influenced by the residence 
(contact) time between the drug and the epithelial 
tissue. The mucociliary clearance is inversely 
related to the residence time and therefore 
inversely proportional to the absorption of drugs 
administered.  
 
Physiological factors: 
Effect of Deposition on Absorption: Deposition 
of the formulation in the anterior portion of the 
nose provides a longer nasal residence time. The 
anterior portion of the nose is an area of low 
permeability while posterior portion of the nose 
where the drug permeability is generally higher, 
provides shorter residence time.  
 
Effect of Pathological Condition: Intranasal 
pathologies may affect the nasal mucociliary 
transport process and/or capacity for nasal 
absorption.  
  
 
Figure 4: Effect of mucociliary clearance on nasal drug absorption37 
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Figure 5: Effect of pathological conditions on nasal mucociliary clearance. 
 
 
Challenges and Oppurtunities for Nasal 
Delivery Systems: [38] 
Existing nasal delivery devices such as spray 
pumps and pipettes cannot fully exploit the 
described potential advantages of nasal delivery. 
A large fraction of the dose is deposited on the 
anterior segment lined by skin, which is not the 
target for either topical drugs or systemic drugs. 
Drugs transported along the floor of the nose may 
cause bad taste and irritation and reduce patient 
acceptance. Finally, inadequate and variable 
deposition in the remote region housing the 
openings to the sinuses and middle ears, as well 
as the olfactory region, represents a real 
challenge for extended use of nasal 
administration of drugs and vaccines. This 
applies in particular to the new advanced and 
expensive drugs requiring demanding 
combination of reliable dosing, high patient 
compliance and reproducible bio-availability to 
ensure their efficacy and safety. Regarding actual 
formulation, most nasal products are currently 
formulated as liquids and delivered by metered 
spray pumps. Liquid formulations can be limited 
by the solubility, stability and dose volume. 
Powders, on the other hand, are more stable and it 
is easier to customize the size and surface 
properties. Some studies indicate reduced local 
irritation and more rapid absorption of powders. 
Bioactis  Ltd. (“Bioactis”; CEO, Ryoichi Nagata, 
MD, PhD) has been developing nasal devices, 
which are medical devices that deliver drugs to 
the nose.  
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Figure 6: Nasal Bioavailability-Problems, Challenges & Solutions. 
 
 
Current approaches for nasal permeation 
enhancement: 
Bioavailability of nasally administered drugs is 
particularly restricted by low drug solubility, 
rapid enzymatic degradation in nasal cavity, poor 
membrane penetration and rapid MCC. Thus 
several approaches have been suggested to 
overcome these limitations. 
 
Prodrugs: 
Intranasal drugs are commonly administered as 
solutions or as powder formulations which need 
to undergo a dissolution process before 
absorption. Lipophilic drugs easily pass through 
biomembranes, however they are poorly water 
soluble. In this way, they should be administered 
as a prodrug with higher hydrophilic character in 
order to make possible the production of an 
aqueous nasal formulation with a suitable 
concentration. Once in the blood stream, the 
prodrug must be quickly converted to the parent 
drug. Kao et al. produced various prodrugs of L-
Dopa and observed that their solubility enhanced 
significantly in comparison with the parent drug, 
allowing, hence, the development of adequate 
nasal formulations [39]. Similar results were 
obtained for testosterone which is also poorly 
water-soluble [40]. In contrast, very hydrophilic 
polar drugs may not have ability to cross 
biomembranes. Thereby, if they are administered 
as prodrugs with higher lipophilic character, the 
penetration through the membrane may increase 
[41]. Some researches have also used the prodrug 
approach for improving enzymatic stability of 
drugs. For example, Yang et al stated that L-
aspartate- β-ester prodrug of acyclovir was more 
permeable and less labile to enzymatic hydrolysis 
than its parent drug [42]. In addition, the potential 
use of prodrugs to protect peptide drugs from 
nasal enzymatic degradation has been discussed 
and suggested as a powerful strategy to increase 
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the bioavailability of peptides when intranasally 
administered [43, 44].  
 
Co-Solvents: 
An alternative approach to the use of prodrugs in 
order to increase drug solubility is the use of co-
solvents[43]. Co-solvents most used in intranasal 
formulations include glycerol, ethanol, 
propyleneglycol and polyethylene glycol and may 
be of the most importance since they are 
nontoxic, pharmaceutically acceptable and 
nonirritant to nasal mucosa.  
 
Enzymatic inhibitors: 
Nasal mucus layer and nasal mucosa act as 
enzymatic barriers during nasal drug delivery, 
because they have a wide variety of enzymes. 
Various approaches have been used to avoid 
enzymatic degradation, including the use of 
proteases and peptidases inhibitors. For example, 
bestatine and comostate amylase are used as 
aminoptidases inhibitors and leupeptine and 
aprotinin as trypsine inhibitors probably involved 
in the degradation of calcitonin [44]. 
Furthermore, bacitracin, amastatin, boroleucin 
and puromycin [44-46] have been used to avoid 
enzymatic degradation of drugs such as leucine 
enkephalin [47,48] and human growth hormone 
[49]. Finally, enzymatic inhibition can also be 
achieved using certain absorption enhancers (bile 
salts and fusidic acid) [42]. It is demonstrated that 
disodium EDTA, an absorption enhancer, reduces 
enzymatic degradation of beta sheet breaker 
peptide used for the treatment of Alzheimer’s 
disease [50]. 
 
Permeation enhancers: 
Small and large hydrophilic drugs may be poorly 
permeable across nasal epithelium and may show 
an insufficient bioavailability. Their permeation 
can improve by administered in combination with 
absorption enhancers which induce reversible 
modifications on the structure of epithelial 
barrier. 
 
 
Table 1: Mucosal penetration enhancers and mechanisms 
of action.[51-59]. 
Classification Examples  Mechanism 
Surfactants Anionic: Sodium 
lauryl sulphate 
Cationic: 
Cetylpyridinium 
Chloride Nonionic: 
Poloxamer, Span,  
Tween 
Perturbation of 
intercellular lipids,  
Protein domain 
integrity, 
Distrusts 
membrane, 
Bile salts Sodium 
glycodeoxycholate,  
Sodium glycocholate, 
Sodium 
taurodeoxycholate,  
Distrusts 
membrane, 
Open tight 
junctions, 
Mucolytic activity 
Cyclodextrins 
 
α, β, γ Cyclodextrin, 
Methylated  
β–Cyclodextrins 
Inclusion of 
membrane 
Compounds, 
Open Tight 
junctions 
Fatty acids  Oleic acid , Lauric 
acid,  Caprylic acid, 
Phosphotidylcholine 
Increase fluidity of 
phospholipid 
domains, 
Distrusts membrane 
Cationic 
compounds 
Poly-L-arginine, L-
lysine 
Ionic interaction 
with negative 
charge on the 
mucosal surface 
Chelators  EDTA, Citric Acid, 
Sodium citrate,  
Interfere with Ca 
Polyacrylates 
+ Ve Charged 
polymers 
Chitosan, Trimethyl 
chitosan 
 
Ionic interaction 
with negative 
charge on the 
mucosal surface 
Bioadhesive 
Materials 
Carbopol, Starch, 
Chitosan 
Reduce nasal 
clearance, 
Open tight 
junctions 
 
Table 2: Various intranasal drug delivery systems and their 
purpose. 
 
Drug Delivery 
system 
Purpose 
Pentazocine60 Microspheres Avoiding first pass 
effect 
Ketorolac 
Trimethamine61 
Microspheres Avoid gastric 
complications 
Sildenafil Citrate62 Microspheres Avoid first pass 
metabolism 
Metoclopramide 
HCl63 
Microspheres Permeation 
enhancement 
Propranolol HCl64 Microspheres Open tight junction 
without cell 
damage 
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N6 
Cyclopentyladenosi
ne65 
Microspheres Selective brain 
targeting 
Propranolol HCl66 Microspheres Avoiding first pass 
effect 
Ondansetron67,68 Microspheres Avoiding first pass 
effect and  improve 
therapeutic 
efficacy 
Domperidone69 Microspheres Selective brain 
targeting 
Sumatriptan 
Succinate70 
Microspheres Avoid hepatic first 
pass metabolism 
and brain targeting 
Clonazepam71 Microspheres Brain targeting 
Clonazepam72 Microemulsion Brain targeting 
Valproic Acid73 Microemulsion Enhanced 
bioavailability with 
brain targeting 
Clobazam74 Microemulsion Brain targeting 
Lomotrigone75 Microemulsion Brain targeting 
Lorazepam76-79 Microemulsion Brain targeting 
Sumatriptan80-85 Microemulsion Enhanced the 
bioavailability 
Zolmitriptan86 Microemulsion Enhanced 
bioavailability 
Zolmitriptan87 Microemulsion Enhanced 
bioavailability & 
rapid onset of 
action 
Eucalyptus oil88 Microemulsion Enhanced 
bioavailability with 
brain targeting 
Nimodipine89 Microemulsion Enhanced 
solubility and brain 
targeting 
Nobiletin90 Microemulsion Improve 
bioavailability in 
the brain 
Tacrine91 Microemulsion Targeting to brain 
Zolmitriptan92 Microemulsion Targeting to brain 
Diazepam93 Microemulsion Rapid absorption 
Raltitrexe94 Microemulsion Targeting to brain 
tissue 
Sildenafil Citrate95 Microemulsion Improve 
bioavailability with 
shorter Tmax 
Insulin96 Microemulsion Enhanced the 
Bioavailability  
Midazolam97 Microemulsion To investigate the 
pharmacokinetic & 
pharmacodynamic 
profile 
Tetanus toxoid98 Liposome Improved immun 
responce 
Insulin99 Liposome Increased insulin 
permeability 
Desmopressin100 Liposome Enhancement of 
antidiuresis 
Diphenhydramine101 Liposome Increased drug 
retention in the 
nasal cavity 
Insulin, calcitonin102 Polyacrylic 
acid gel 
Enhanced 
absorption 
Insulin103 Powder Improve 
bioavailability 
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